Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study

Clinical Microbiology and Infection

Volumn 21, Issue 5, 2015, Pages 510.e1-510.e9

  Nozza, S ^a   Galli, L ^a   Antinori, A ^b   Chiappetta, S ^a,c   Mazzotta, F ^d   Zaccarelli, M ^b   Ottou, S ^b   De Battista, D ^e   Pogliaghi, M ^a,c   Di Pietro, M ^d   Malnati, M ^e   Ripa, M ^c   Bonora, S ^f   Lazzarin, A ^a,c  

^a OSR Scientific Institute   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d SS Annunziata Hospital   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

Author keywords

Antiretroviral therapy; Human immunodeficiency virus; Maraviroc; Naive patients; Nucleoside nucleotide reverse transcriptase inhibitor sparing regimen

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; GLUCOSE; LIPID; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; VIRUS DNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLOHEXANE DERIVATIVE; DRUG COMBINATION; LOPINAVIR; LOPINAVIR-RITONAVIR DRUG COMBINATION; RITONAVIR; TRIAZOLE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PARAMETERS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MIDDLE AGED; MULTICENTER STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; VIRUS LOAD; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; PROCEDURES; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CYCLOHEXANES; DNA, VIRAL; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LOPINAVIR; MALE; PROSPECTIVE STUDIES; RITONAVIR; TREATMENT OUTCOME; TRIAZOLES; VIRAL LOAD;

EID: 84930510113     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.12.006     Document Type: Article

References (27)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents March 12, 2012, 1-240. Department of Health and Human Services, Available at:. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
2. Reynes J., Trinh R., Pulido F., Soto-Malave R., Gathe J., Qaqish R., et al. Lopinavir/ritonavir combined with raltegravi er tenofovir/emtricitabine in antiretroviral-naive subjects: 96-weeks results of the PROGRESS study. AIDS Res Hum Retroviruses 2013, 29(2):256-265.
3. Cahn P. Dual therapy with lopinavir/ritonavir (LPV/r) and lamivudine (3TC) is non-inferior to standard triple drug therapy in naive HIV-1 infected subjects: 48-week results of the GARDEL study 2013, the GARDEL Study Group, 14th European AIDS Conference, Brussels, abstract LBPS7/6.
4. Raffi F., Babiker A.G., Richert L., Molina J.M., George E.C., Antinori A., et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014 Nov 29, 384(9958):1942-1951.
5. Gulick R.M., Fatkenheuer G., Burnside R., Hardy W.D., Nelson M.R., Goodrich J., et al. Five-year safety evaluation of maraviroc in HIV-1-infected, treatment-experienced patients. JAcquir Immune Defic Syndr 2014, 65:78-81.
6. Moyle G.J., Wildfire A., Mandalia S., Mayer H., Goodrich J., Whitcomb J., et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. JInfect Dis 2005, 191:866-872.
7. Hardy W.D., Gulick R.M., Mayer H., Fätkenheuer G., Nelson M., Heera J., et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. JAcquir Immune Defic Syndr 2010, 55(5):558-564.
8. Mills A., Mildvan D., Podzamczer D., Fätkenheuer G., Leal M., Than S., et al. Maraviroc once daily nucleoside analog-sparing regimen in treatment-naïve patients: randomised, open-label pilot study. JAIDS 2013, 62(2):164-170.
9. Stellbrink H.-J., Pulik P., Szlavik J., Murphy D., Lazzarin A., Portilla J., et al. Maraviroc (MVC) dosed once daily with darunavir/ritonavir (DRV/r) in a 2 drug-regimen compared to emtricitabine/tenofovir (TDF/FTC) with DRV/r; 48-week results from MODERN (study A4001095). AIDS 2014, 20th International AIDS Conference. July 20-25, 2014. Melbourne. Abstract TUAB0101.
10. Malnati M.S., Scarlatti G., Gatto F., Salvatori F., Cassina G., Rutigliano T., et al. Auniversal real-time PCR assay for the quantification of group HIV-1 proviral load. Nat Protoc 2008, 3(7):1240-1248.
11. Brown T.T., Ross A.C., Storer N., Labbato D., McComsey G.A. Bone turnover, osteoprogesterin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther 2011, 16:1063-1072.
12. Descamps D., Assoumou L., Chaix M.L., Chaillon A., Pakianather S., de Rougemont A., et al. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. JAntimicrob Chemother 2013, 85:2626-2631.
13. Taiwo B., Acosta E.P., Ryscavage P., Berzins B., Lu D., Lalezari J., et al. Virologic response, early HIV-1 decay and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. JAcquir Immune Defic Syndr 2013, 64:167-173.
14. Antinori A., Marcotullio S., Ammassari A., Andreoni M., Angarano G., Armignacco O., et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol 2012, 35(2):113-159.
15. Calcagno A., Nozza S., Gonzalez de Requena D., Galli A., D'Avolio A., Simiele M., et al. Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. JAntimicrob Chemother 2013, 68(7):1686-1688.
16. Okoli C., Siccardi M., Thomas-William S., Dufty N., Khonyongwa K., Ainsworth J., et al. Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. JAntimicrob Chemother 2012, 67:671-674.
17. Avettand-Fenoel V., Blanche S., Le Chenadec J., Scott-Algara D., Dollfus C. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study. JInfect Dis 2012, 205(10):1520-1528.
18. + T cells are highly permissive to HIV-1 infection. JImmunol 2010, 184:1604-1616.
19. Islam S., Shimizu N., Hoque S.A., Jinno-Oue A., Tanaka A., Hoshino H. CCR6 functions as a new coreceptor for limited primary human and simian immunodeficiency viruses. PLoS One 2013, 8(8):e73116.
20. Lafferty M.K., Sun L., DeMasi L., Lu W., Garzino-Demo A. CCR6 ligands inhibit HIV by inducing APOBEC3G. Blood 2010, 115(8):1564-1571.
21. Rossetti B., Bianco C., Bellazzi L.I., Bruzzone B., Colao G., Corsi P., et al. Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type-1 infected patients in clinical practice: role of different tropism results and of concomitant treatments. AIDS Res Hum Retroviruses 2014, 30:17-24.
22. Nozza S., Galli L., Bigoloni A., Nicola G., Pogliaghi M., Cossarini F., et al. Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. JAcquir Immune Defic Syndr 2011, 56(4):e113-e115.
23. + T lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol 2002, 102:154-161.
24. + T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. JInfect Dis 2006, 194:29-37.
25. Cossarini F., Galli A., Galli L., Bigoloni A., Salpietro S., Vinci C., et al. Immune recovery and T cell subset analysis during effective treatment with maraviroc. JAntimicrob Chemother 2012, 67(10):2474-2478.
26. Cocchi F., DeVico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8{thorn} T cells. Science 1995, 270:1811-1815.
27. MacInnes A., Lazzarin A., Di Perri G., Sierra-Madero J.G., Aberg J., Heera J., et al. Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial. HIV Clin Trials 2011, 12(1):24-36.